120 Ethnic Status and Socioeconomic Deprivation in Never Smokers Compared with Current Smokers with advanced NSCLC
The UK has many disparities in health care delivery and outcomes within different ethnic, socioeconomic and racial groups1. Some inequality may relate to behaviours such as smoking. NHS Digital reported that smoking rates in England were lowest amongst patients from Asian or African backgrounds. Smoking rates are highest amongst patients in lower socioeconomic groups2. We reviewed rates of smoking and how they related to ethnicity and socioeconomic status amongst patients referred to our unit, to see if our patient cohort reflects this and to help stratify intervention for at risk groups. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lydia Gabriel, Jaishree Bhosle, Michael Davidson, Anna Minchom, Charlotte Milner-Watts, Mary O'Brien Tags: Other Source Type: research
121 Ongoing impact of the pandemic on cancer services
The impact of the response to the COVID pandemic on primary care practice and the subsequent reduction in the diagnosis of lung cancer is well acknowledged. We explored the potential ongoing long lasting effect from the pandemic measures with regards to lung cancer diagnoses. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Rodanthe Nixon, Holly Emms, Carlos Pereira Chilima, Samreen Afroz, Sophie Goodrum Tags: Other Source Type: research
122 Social Isolation and Lung Cancer: Does This Impact the Length of Time on The Lung Cancer Pathway Or Uptake Of MDT Recommended Treatments
“Bridging The Gap” report by UKLCC (2022) suggested addressing health inequalities in lung cancer has a significant impact on patient outcomes. LCNUK investigated a possible correlation between social isolation (lack of social contacts and having few people to interact with regularly) and time o n pathway. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Victoria Anderson, Pamela Dalrymple, Gemma Crowley, Paula Shephard, Chole Holmes, Julia McAdams, June Morley, Elliot Sarah, Sarah Ivey, Kate Bentley, George Bate Bate, Paul English, Georgina Russell, Layla Bostock Tags: Other Source Type: research
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England
ALK Positive Lung Cancer (UK) is a charity providing support and advocacy for patients of ALK-positive NSCLC. We wish to measure our success in reaching patients but there is an absence of a precise number of cases in the UK as health authorities do not specifically code ALK-positive LC. Studies suggest that ALK-positive LC comprises 3% –5% of NSCLC diagnoses. Taking a midpoint of 4% and 31,000 NSCLC diagnoses per year in England, the number of new cases of ALK-positive LC would be 1,240 pa. Assuming a median OS of 68 months, this suggests an estimated 7,000 patients in England. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Duncan Edmonstone, Debra Montague Tags: Other Source Type: research
124 Telling patients they have lung cancer on the telephone
We introduced a Virtual Lung Cancer Assessment Clinic in April 2016 in order to speed up the diagnostic process whilst enhancing patient experience with resulting cost savings This replaces the first outpatient and enables patients to be seen at the first OPA with completed investigations and results available. We have recently re -evaluated this service. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Joanne Wilson Tags: Other Source Type: research
125 VTE Risk Awareness in People with Lung Cancer in the UK: Results from a Patient-led National Survey
A high incidence of venous thromboembolism (VTE) is reported in people with lung cancer (PwLC). PwLC with certain gene mutations (alterations) (e.g. ALK positive) are at higher risk of VTE than people who don't have the gene mutation, VTE can negatively affect quality of life (QoL) and maybe misattributed to other causes by PwLC due to limited awareness. We aim to explore the perspectives on VTE, treatment for VTE and the impact on the lives of PwLC and their carers. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Debra Montague, Farzana Haque, Young Annie, Mike Lind, Graham Lavender, David Allsup, Anthony Maraveyas, Cecilia Pompili Tags: Other Source Type: research
126 Exploring Real-World Treatment Patterns and Outcomes in Stage IIIA N2 Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA N2 NSCLC presents a significant clinical challenge, with suboptimal survival rates despite therapeutic advancements, highlighting the need for more effective treatments. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Eleni Josephides, Roberta Dunn, Mona Faranghi, Annie-Rose Henry, John Pilling, Karen Harrison-Phipps, Shahreen Ahmad, Michael Skwarski, Benjamin Taylor, James Spicer, Alexandros Georgiou, Sharmistha Ghosh, George Santis, Ronan Breen, Mieke Van Hemelrijck, Tags: Other Source Type: research
127 Perceptions of Health care professionals on Sleep disturbance amongst patients with Lung Cancer – Quality Improvement project (QIP)
Sleep disturbance is a common but potentially under-recognised problem in cancer patients which is associated with poor quality of life. ESMO along with other international bodies recommends routine screening in all cancer patients but there may be barriers to HCPs achieving this. As a part of quality improvement project, we have conducted survey to understand the current perceptions of the health care professionals (HCPs) to develop services aimed to improve patient care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Jaya Lakshmi Vangara, Mick Button Tags: Other Source Type: research
128 90 day admissions and mortality in lung cancer patients
NICE guidelines for lung cancer are based on fit and ≤70 year old patients. However, in the Cheshire and Merseyside region 60% are aged ≥70, with the second highest rate of co-morbidities in the UK (1). Our aim was to investigate factors associated with poor 90-day outcomes following systemic anti-cancer therapy (SACT). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: David Cobben, Pawel Sokal, Katherine Piddock, Helen Wong, Bridget Taylor, Carles Escriu Tags: Other Source Type: research
129 Enhancing Assessment and Care Management for patients in Emergency Department and Inpatient Wards with an Incidental Funding of Lung Cancer – Early Pilot Project Case Studies
Lung Cancer is known to be a complex and evolving tumour site with many of the patient's progressed into pathways being diagnosed outside of primary care through incidental findings on diagnostic tests. It is common for patients to present to acute hospitals, notably Emergency Department and Same Day Emergency Care settings, for one reason and be given a cancer diagnosis. The primary presenting condition is often the core focus e.g. chest infection, trauma injury – with the incidental lung cancer diagnosis referred for future outpatient clinic follow-up. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Richard Sterry, Andrea Worsdale, Leah Taylor, Mark Weatherhead Tags: Other Source Type: research
130 A review of patients diagnosed with non-small cell lung cancer, stage I-II disease and a performance status of 0 –1 over the past 10 years
Expected lung cancer outcomes are derived from the TMN staging at diagnosis. We sought to understand local practice and trends in a targeted population over the past 10 years. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Gareth Trevelyan, Ben Probyn, John Corcoran, Timothy Howell, Aparna Iyer, Lindsey Taylor, Thomas Nicholson, David Waine, Adrian Marchbank, Cyrus Daneshvar Tags: Other Source Type: research
131 Early stage lung cancer outcomes – a 10 year review of surgery and radiotherapy in patients with performance status 0-1 and Stage I and II NSCLC lung cancer
Historically low regional surgical resection rates combined with the introduction of SABR in the past 10 years may impacted on our long term outcomes in patients with a good performance status and early stage lung cancer. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Gareth Trevelyan, Ben Probyn, John Corcoran, Timothy Howell, Aparna Iyer, Lindsey Taylor, Thomas Nicholson, David Waine, Adrian Marchbank, Cyrus Daneshvar Tags: Other Source Type: research
132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment
The National Lung Cancer Audit (NLCA) reported in November 2023 that 79% of patients with non-small cell lung cancer (NSCLC) with stage I or II disease and a performance status (PS) of 0-2 received curative intent treatment (audit standard ≥80%), and 60% of patients with NSCLC stage IIIA, PS 0-2, received curative intent treatment. Furthermore, 61% of patients with NSCLC stage IIIB–IV, PS0-1 received systemic anticancer treatment (audit standard ≥65%). To compare against national standards, a retrospective review was performed. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Karen Clayton, Larissa Griffiths, Joanna Gallagher, Bethan Clayton Tags: Other Source Type: research
133 Review of Advanced Lung cancer treatment in relation to the NLCA report
Lung cancer has the lowest fiver year survival. Prognosis is far worse in people with advanced stage. National Lung cancer Audit 2023 (data period 2021) results showed that only 61% patients with non-small cell lung cancer (stage IIIB - IV, PS 0-1) had systemic cancer treatment. We aim to see if it was a similar trend for the year 2022 and to explore the reasons for any low treatment rate. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lokesh Kovvuri, Viktoria Oakden, Shahul Leyakathali Khan Tags: Other Source Type: research
134 Lung cancer patients ’ views, experiences of treatment and communications preferences – findings from the Global Lung Cancer Coalition's fourth annual global survey
In 2023, the Global Lung Cancer Coalition (GLCC), a partnership of 43 non-government patient organisations across 30 countries, ran its fourth annual global patient experience survey to explore patients ’ involvement in decision-making and preferred methods of contact with their treatment teams. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Aoife McNamara, Jackie Fenemore, Jesme Fox, Elizabeth Beck Tags: Other Source Type: research
